April 5, 2021 10:41 AM EDTUpdated April 6, 02:21 PM
News Briefing

Watch out, Bris­tol My­ers — J&J is right be­hind you; Blake By­ers leaps out from GV to do his own thing

John Carroll

Editor & Founder

We’ve learned that J&J has now fin­ished its rolling ap­pli­ca­tion for the BC­MA-tar­get­ed cil­ta-cel, which one an­a­lyst be­lieves will put them about 8 or 9 …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

Lil­ly's board un­der­goes more changes; Mer­ck strat­e­gy chief joins Roger Perl­mut­ter at Eikon

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs 

Halozyme with­draws Evotec ac­qui­si­tion pro­pos­al af­ter biotech is 'un­will­ing to en­gage'

From vac­cines to psy­che­delics, five drug­mak­ers on what could change un­der a Trump ad­min­is­tra­tion

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times